TGF-β downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients

263Citations
Citations of this article
154Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The activating receptor NKG2D, expressed by natural killer (NK) cells and CD8+ T cells, has a role in the specific killing of transformed cells. We examined NKG2D expression in patients with glioblastoma multiforme and found that NKG2D was downregulated on NK cells and CD8+ T cells. Expression of NKG2D on lymphocytes significantly increased following tumor resection and correlated with an increased ability to kill NKG2D ligand-positive tumor targets. Despite the presence of soluble NKG2D ligands in the sera of glioblastoma patients, NKG2D downregulation was primarily caused by tumor-derived tumor growth factor-β, suggesting that blocking of this cytokine may have therapeutic benefit. © The Author(s) 2009.

Author supplied keywords

Cite

CITATION STYLE

APA

Crane, C. A., Han, S. J., Barry, J. J., Ahn, B. J., Lanier, L. L., & Parsa, A. T. (2010). TGF-β downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro-Oncology, 12(1), 7–13. https://doi.org/10.1093/neuonc/nop009

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free